Humana Reports Q3 2026 Earnings with Upward Full-Year Guidance Amid Star Rating Headwinds
Humana (HUM) reported third-quarter results characterized by a significant contrast between operational strength and regulatory headwinds. While the company posted an adjusted loss per share of $0.70 due to Star rating impacts, its year-to-date adjusted EPS reached $17.17, exceeding initial guidance. Management responded to strong performance by raising full-year 2026 GAAP EPS guidance from at least $6.52 to at least $15.09. The company is seeing robust growth in its CenterWell senior primary care segment and Medicaid membership. Despite these gains, Humana faces rising costs for 2027, specifically a projected 14% to 15% trend in Part D prescription drug costs driven by high-cost pharmaceuticals. To bolster liquidity, the company expects approximately $900 million in pretax proceeds from the divestment of a minority interest in Gentiva during the fourth quarter.
Topics: earnings report guidance revision insurance segment performance membership growth